Nicholas Naclerio bought $4.0M of Alamar Biosciences (ALMR)
Executed Apr 20, disclosed Apr 21, the same day.
Over the 21 trading sessions from the disclosed entry session (Apr 20), the stock returned -6.6% (delay-adjusted); from the execution session (Apr 20), -6.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Nicholas Naclerio (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Alamar Biosciences, Inc. (ALMR). Across 1 priced purchase filing, the average 21-session return was -6.6% from execution and -6.6% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of ALMR (235,294 sh × $17.00, as filed), executed Apr 20.
Healthcare · Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and service…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→